14/10/2026
More fabulous work from Dr Lucy Gately and the BRAIN team at EANO 2026! 🔥
🔎 MGMT is a predictive biomarker in glioblastoma. However, significant within-group heterogeneity remained. Additional factors beyond MGMT methylation continue to shape survival outcomes.
🔎 BEACON is a self-referral, population accessible registry, collecting patient-reported outcomes. Preliminary findings demonstrate favourable usability and user-satisfaction with BEACON. Now the team is looking forward to focus on implementation and leveraging BEACON for translational and clinical research.
🔎 The BRAIN Registry has been involved in the development of the Real-World Evidence Glioma Council’s suggested structure of categories in registry development, sharing expertise to guide the next generation of lower grade glioma registries.